HK1145839A1 - N-phenyl-dioxo-hydropyrimidines useful as hepatitis c virus (hcv) inhibitors - Google Patents

N-phenyl-dioxo-hydropyrimidines useful as hepatitis c virus (hcv) inhibitors

Info

Publication number
HK1145839A1
HK1145839A1 HK11100075.5A HK11100075A HK1145839A1 HK 1145839 A1 HK1145839 A1 HK 1145839A1 HK 11100075 A HK11100075 A HK 11100075A HK 1145839 A1 HK1145839 A1 HK 1145839A1
Authority
HK
Hong Kong
Prior art keywords
hepatitis
useful
hcv
hydropyrimidines
dioxo
Prior art date
Application number
HK11100075.5A
Other languages
English (en)
Inventor
Pamela L Donner
John T Randolph
Allan C Krueger
David A Betebenner
Douglas K Hutchinson
Dachun Liu
Yaya Liu
Kenton L Longenecker
Clarence J Maring
John K Pratt
Todd W Rockway
Kent D Stewart
Rolf Wagner
David M Barnes
Shuang Chen
Ii Thaddeus S Franczyk
Yi Gao
Anthony R Haight
John E Hengeveld
Rodger F Henry
Brian J Kotecki
Xiaochun Lou
Geoff G Z Zhang
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of HK1145839A1 publication Critical patent/HK1145839A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52Two oxygen atoms
    • C07D239/54Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52Two oxygen atoms
    • C07D239/54Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/553Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
HK11100075.5A 2007-09-17 2011-01-05 N-phenyl-dioxo-hydropyrimidines useful as hepatitis c virus (hcv) inhibitors HK1145839A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97288707P 2007-09-17 2007-09-17
US9679408P 2008-09-13 2008-09-13
PCT/US2008/076594 WO2009039135A1 (en) 2007-09-17 2008-09-17 N-phenyl-dioxo-hydropyrimidines useful as hepatitis c virus (hcv) inhibitors

Publications (1)

Publication Number Publication Date
HK1145839A1 true HK1145839A1 (en) 2011-05-06

Family

ID=40091991

Family Applications (1)

Application Number Title Priority Date Filing Date
HK11100075.5A HK1145839A1 (en) 2007-09-17 2011-01-05 N-phenyl-dioxo-hydropyrimidines useful as hepatitis c virus (hcv) inhibitors

Country Status (15)

Country Link
US (2) US8178548B2 (el)
EP (3) EP2203430B1 (el)
JP (1) JP5726527B2 (el)
CN (3) CN101918369B (el)
AT (1) ATE512954T1 (el)
CA (1) CA2699989C (el)
DK (1) DK2203430T3 (el)
HK (1) HK1145839A1 (el)
HR (1) HRP20110632T1 (el)
MX (1) MX2010002904A (el)
PL (1) PL2203430T3 (el)
PT (1) PT2203430E (el)
RU (1) RU2542099C2 (el)
WO (1) WO2009039135A1 (el)
ZA (1) ZA201002690B (el)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ618277A (en) 2007-09-17 2015-07-31 Abbvie Bahamas Ltd Uracil or thymine derivative for treating hepatitis c
ATE512954T1 (de) 2007-09-17 2011-07-15 Abbott Lab Als inhibitoren des hepatitis-c-virus (hcv) geeignete n-phenyldioxohydropyrimidine
EP2639226B1 (en) 2007-09-17 2016-08-31 AbbVie Bahamas Ltd. Anti-infective pyrimidines and uses thereof
PE20110409A1 (es) 2008-07-23 2011-06-22 Hoffmann La Roche Compuestos heterociclicos antiviricos
BRPI0920513A2 (pt) 2008-09-26 2019-09-24 F Hoffamann La Roche Ag derivados de pirina ou pirazina para tratar hcv
AU2009309813A1 (en) 2008-10-30 2010-05-06 F. Hoffmann-La Roche Ag Heterocyclic antiviral arylpyridone derivatives
WO2010072598A1 (en) 2008-12-22 2010-07-01 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
MX2011008641A (es) 2009-03-06 2011-09-06 Hoffmann La Roche Compuestos heterociclicos antivirales.
PE20120519A1 (es) * 2009-03-24 2012-06-03 Abbvie Bahamas Ltd Proceso para preparar (e)-n-(4-(3-tertbutil-5-(2, 4-dioxo-3, 4-dihidropirimidin-1 (2h)-il)-2-metoxiestiril)fenil)metanosulfonamida
BRPI1016167A2 (pt) * 2009-04-25 2019-07-16 Hoffmann La Roche compostos heterocíclicos antivirais.
AR077004A1 (es) 2009-06-09 2011-07-27 Hoffmann La Roche Compuestos heterociclicos antivirales
AU2010264802A1 (en) 2009-06-24 2012-01-19 F. Hoffmann-La Roche Ag Heterocyclic antiviral compound
CA2768924A1 (en) 2009-09-21 2011-03-24 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
WO2011053617A1 (en) 2009-10-30 2011-05-05 Boehringer Ingelheim International Gmbh Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin
TW201129362A (en) * 2009-11-21 2011-09-01 Hoffmann La Roche Heterocyclic antiviral compounds
MX2012007076A (es) * 2009-12-18 2012-07-20 Boehringer Ingelheim Int Terapia combinada de hcv.
US9216952B2 (en) 2010-03-23 2015-12-22 Abbvie Inc. Process for preparing antiviral compound
EP2590960B1 (en) 2010-07-07 2014-06-11 F.Hoffmann-La Roche Ag Heterocyclic antiviral compounds
US8975443B2 (en) 2010-07-16 2015-03-10 Abbvie Inc. Phosphine ligands for catalytic reactions
US9255074B2 (en) 2010-07-16 2016-02-09 Abbvie Inc. Process for preparing antiviral compounds
EA201790723A1 (ru) 2010-07-16 2017-12-29 ЭббВи Айэленд Анлимитед Компани Способ получения противовирусных соединений
KR101774742B1 (ko) 2010-07-16 2017-09-11 애브비 아일랜드 언리미티드 컴퍼니 촉매 반응용 포스핀 리간드
CA2829768A1 (en) * 2011-03-18 2012-09-27 Abbvie Inc. Formulations of phenyl uracil compounds
US8989328B2 (en) * 2013-03-14 2015-03-24 Qualcomm Incorporated Systems and methods for serial communication
SI3043803T1 (sl) 2013-09-11 2022-09-30 Emory University Nukleotidne in nukleozidne sestave in njihova uporaba
WO2015197028A1 (en) * 2014-06-28 2015-12-30 Sunshine Lake Pharma Co., Ltd. Compounds as hepatitis c virus (hcv) inhibitors and uses thereof in medicine
US11192914B2 (en) 2016-04-28 2021-12-07 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
WO2018085170A1 (en) * 2016-11-01 2018-05-11 Merck Sharp & Dohme Corp. Substituted 6-membered aryl or heteroaryl allosteric modulators of nicotinic acetylcholine receptors
CN110483496B (zh) * 2019-07-17 2021-05-04 杭州市西溪医院 一类具有尿嘧啶-苯并噻唑结构衍生物、其制备方法及抗hcv药物的应用
EP3819006A1 (en) 2019-11-05 2021-05-12 Technische Universität Dresden Compounds with thymine skeleton for use in medicine
CN111018910A (zh) * 2019-12-05 2020-04-17 上海应用技术大学 一种铜催化合成含芳环α-羟基膦酸酯的方法
CN111518036A (zh) * 2020-04-29 2020-08-11 杭州勇诚睿生物科技有限公司 一种达沙布韦关键中间体的制备方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4239888A (en) 1974-11-04 1980-12-16 Pfizer Inc. 1-Phenyluracils
JPS60243017A (ja) * 1984-05-16 1985-12-03 Kyowa Hakko Kogyo Co Ltd 抗けいれん組成物
AU627906B2 (en) 1989-07-14 1992-09-03 Nissan Chemical Industries Ltd. Uracil derivatives and herbicides containing the same as active ingredient
US5084084A (en) 1989-07-14 1992-01-28 Nissan Chemical Industries Ltd. Uracil derivatives and herbicides containing the same as active ingredient
DE69129998T2 (de) 1990-02-15 1998-12-24 Takeda Chemical Industries, Ltd., Osaka Pyrimidindionderivate, deren Herstellung und Verwendung
NL9001075A (el) * 1990-05-04 1991-12-02 Duphar Int Res
EP0489480A1 (en) * 1990-12-05 1992-06-10 Nissan Chemical Industries Ltd. Uracil derivatives and herbicides containing the same as active ingredient
JPH05213755A (ja) 1992-02-07 1993-08-24 Nikko Kyodo Co Ltd 肝臓障害治療薬
DE19528305A1 (de) 1995-08-02 1997-02-06 Bayer Ag Substituierte Phenyluracile
US6380387B1 (en) 1999-12-06 2002-04-30 Hoffmann-La Roche Inc. 4-Pyrimidinyl-n-acyl-l phenylalanines
KR100522344B1 (ko) 1999-12-06 2005-10-20 에프. 호프만-라 로슈 아게 4-피리미디닐-n-아실-l-페닐알라닌
RU2264395C2 (ru) * 2000-02-04 2005-11-20 Сумитомо Кемикал Компани, Лимитед Производные урацила, гербицидная композиция, способ борьбы с сорняками и промежуточные продукты (варианты)
IL167954A (en) 2000-02-04 2007-10-31 Sumitomo Chemical Co History of pyrimidine
MY164523A (en) * 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
KR100589964B1 (ko) * 2003-06-13 2006-06-19 주식회사 엘지생명과학 C형 간염 바이러스의 억제제
US7163937B2 (en) 2003-08-21 2007-01-16 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
NZ618277A (en) * 2007-09-17 2015-07-31 Abbvie Bahamas Ltd Uracil or thymine derivative for treating hepatitis c
EP2639226B1 (en) 2007-09-17 2016-08-31 AbbVie Bahamas Ltd. Anti-infective pyrimidines and uses thereof
ATE512954T1 (de) 2007-09-17 2011-07-15 Abbott Lab Als inhibitoren des hepatitis-c-virus (hcv) geeignete n-phenyldioxohydropyrimidine
PE20110409A1 (es) 2008-07-23 2011-06-22 Hoffmann La Roche Compuestos heterociclicos antiviricos

Also Published As

Publication number Publication date
EP2548873A1 (en) 2013-01-23
RU2542099C2 (ru) 2015-02-20
CN101918369A (zh) 2010-12-15
PT2203430E (pt) 2011-09-02
CN105294569A (zh) 2016-02-03
RU2010114826A (ru) 2011-10-27
WO2009039135A1 (en) 2009-03-26
ATE512954T1 (de) 2011-07-15
ZA201002690B (en) 2015-12-23
US20090176784A1 (en) 2009-07-09
US8178548B2 (en) 2012-05-15
MX2010002904A (es) 2010-06-02
US8986740B2 (en) 2015-03-24
US20120189580A1 (en) 2012-07-26
CA2699989A1 (en) 2009-03-26
DK2203430T3 (da) 2011-09-26
EP2203430A1 (en) 2010-07-07
EP2377854A1 (en) 2011-10-19
CN105693626A (zh) 2016-06-22
HRP20110632T1 (hr) 2011-10-31
PL2203430T3 (pl) 2011-12-30
JP2010539188A (ja) 2010-12-16
EP2203430B1 (en) 2011-06-15
CN101918369B (zh) 2016-02-24
CA2699989C (en) 2014-03-25
JP5726527B2 (ja) 2015-06-03

Similar Documents

Publication Publication Date Title
HK1145839A1 (en) N-phenyl-dioxo-hydropyrimidines useful as hepatitis c virus (hcv) inhibitors
MX2011009644A (es) Inhibidores del virus de la hepatitis c.
MX2009009473A (es) Compuestos para el tratamiento de hepatitis c.
MX2013002927A (es) Inhibidores del virus de la hepatitis c.
MX2009004888A (es) Inhibidores del virus de la hepatitis c.
MX2009004943A (es) Inhibidores del virus de la hepatitis c.
MX2010008699A (es) Derivados heterociclicos como inhibidores de virus de la hepatitis c.
MX2012004032A (es) Compuestos para el tratamiento de hepatitis c.
MX2010008531A (es) Derivados de bifenilo conformacionalmente restringido para uso como inhibidores del virus de la hepatitis c.
BR112013020042A2 (pt) inibidores de vírus da hepatite c
MX2010001733A (es) Compustos de imidazo[1,2-a]pirazina para tratamiento de infecciones virales tales como hepatitis.
MX2009008439A (es) Nuevos inhibidores de la replicacion del virus de hepatitis c.
MX2010008749A (es) Inhibidores del virus de la hepatitis c.
MX2013003634A (es) Derivados policiclicos heterociclicos y metodos de uso de los mismos para el tratamiento de enfermedades virales.
SI1987038T1 (sl) Hcv ns5b inhibitorji
NZ595186A (en) Di-pyrazolidinyl-biphenylyl compounds for treating hepatitis C virus (HCV) infection
MX2012000959A (es) Inhibidores de los virus flaviviridae.
WO2008021936A3 (en) Hepatitis c virus inhibitors
MX2010001416A (es) Compuesto para el tratamiento de la hepatitis c.
ATE547103T1 (de) Hemmer des hepatitis-c-virus
TW200745004A (en) Novel compounds, their preparation and use
MX2011006631A (es) Inhibidores de proteasa ns3 del virus hcv.
IN2012DN01855A (el)
HK1152705A1 (en) Dihydropyrimidine compounds and use thereof for the treatment of viral diseases
DE602008004317D1 (de) Verbindungen zur behandlung von hepatitis c

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20160917